The recycling of the amyloid precursor protein (APP) from the cell surface via the endocytic pathways plays a key role in the generation of amyloid b peptide (Ab) in Alzheimer disease. We report here that inherited variants in the SORL1 neuronal sorting receptor are associated with late-onset Alzheimer disease. These variants, which occur in at least two different clusters of intronic sequences within the SORL1 gene (also known as LR11 or SORLA) may regulate tissue-specific expression of SORL1. We also show that SORL1 directs trafficking of APP into recycling pathways and that when SORL1 is underexpressed, APP is sorted into Ab-generating compartments. These data suggest that inherited or acquired changes in SORL1 expression or function are mechanistically involved in causing Alzheimer disease.
The recycling of the amyloid precursor protein (APP) from the cell surface via the endocytic pathways plays a key role in the generation of amyloid b peptide (Ab) in Alzheimer disease. We report here that inherited variants in the SORL1 neuronal sorting receptor are associated with late-onset Alzheimer disease. These variants, which occur in at least two different clusters of intronic sequences within the SORL1 gene (also known as LR11 or SORLA) may regulate tissue-specific expression of SORL1. We also show that SORL1 directs trafficking of APP into recycling pathways and that when SORL1 is underexpressed, APP is sorted into Ab-generating compartments. These data suggest that inherited or acquired changes in SORL1 expression or function are mechanistically involved in causing Alzheimer disease.
The accumulation of Ab peptide, a neurotoxic proteolytic derivative of APP, is a central event in the pathogenesis of Alzheimer disease 1 . Accumulation of Ab in the brain is associated with disease-causing inherited variants in the APP 2 , presenilin 1 (PSEN1) 3 presenilin 2 (PSEN2) 4 and apolipoprotein E (APOE) genes 5, 6 . The generation of Ab occurs in several subcellular compartments, but a principal location is during the re-entry and recycling of APP from the cell surface via the endocytic pathway (Fig. 1a) [7] [8] [9] [10] [11] . We reasoned that inherited variants in these pathways might modulate APP processing and thereby affect risk for Alzheimer disease. This concept is supported by prior reports that (i) the expression of several candidate proteins within these pathways (such as SORL1 (ref. 12 ) and VPS35 (ref. 13) ) is reduced in brain tissue from individuals with Alzheimer disease and (ii) reductions in the expression of some of these proteins are associated with increased Ab production [13] [14] [15] . However, it is unclear whether these changes are causal or simply reactive to Alzheimer disease.
To address this question, we investigated genetic associations between Alzheimer disease and SNPs in selected members of the vacuolar protein sorting (VPS) gene family, including VPS35 (16q12); VPS26A (10q21); sortilin SORT1 (1p21-p13); sortilin-related VPS10-containing receptors SORCS1 (10q23-q25), SORCS2 (4p16) and SORCS3 (10q23-q25); and the sortilin-related receptor, low-density lipoprotein receptor class A repeat-containing protein SORL1 (11q23-q24). We tested several SNPs from these genes in six independent data sets that have sufficient power to detect modest gene effects (l s ¼ 1.5). We collected these data sets with restricted ancestral origins in order to minimize the confounding effects of allelic heterogeneity 16, 17 . Indeed, two of these six data sets (Caribbean Hispanic FAD and Israeli Arab), were drawn from population isolates with a limited number of founders 18, 19 .
We divided these six data sets into a 'discovery cohort' composed of families with late-onset familial Alzheimer disease (FAD) and a 'replication cohort' composed of discordant sibships and collections of individuals with Alzheimer disease and normal controls matched for age, gender and ethnic origin. We analyzed the FAD pedigrees in the discovery cohort (124 north European FAD families 20, 21 and 228 Caribbean Hispanic FAD families 22 ; Supplementary Table 1 online) with conservative family-based association (FBAT) methods, which are less sensitive to population stratification. We then reinvestigated positive results from the discovery cohort in the replication cohort (Supplementary Table 1 ). This replication cohort contained (i) northern European individuals from a case-control study (178 individuals with sporadic Alzheimer disease and 242 controls of self-identified Caucasian European ancestry) 20 , (ii) MIRAGE Caucasian sibships (276 Caucasian sibships from the MIRAGE Study) 23, 24 , (iii) MIRAGE African American sibships (238 African American sibships from the MIRAGE Study) 23, 24 and (iv) Israeli Arab affected individuals and controls (all 111 individuals with Alzheimer disease and 114 normal controls were from the Wadi Ara population study) 19, 25 .
We also obtained fully independent replication from a large data set composed of three cohorts of Americans of self-identified European Caucasian ancestries that were separately ascertained, genotyped and analyzed statistically at the Mayo Clinic (1,405 individuals with Alzheimer disease and 2,124 controls; Supplementary Table 1) .
RESULTS

SNPs in SORL1 are associated with late-onset Alzheimer disease
We initially screened at least two SNPs in the intragenic sequences of the SORL1, VPS26A, VPS35, SORCS1, SORCS3, SORCS2 and SORT1 genes for association with Alzheimer disease in the two independent FAD 'discovery data sets' . We did not observe any allelic associations with VPS26A, VPS35, SORCS3 or SORT1 (Supplementary Tables 2  and 3 online) . However, one SNP in SORCS1 (rs7082289: P ¼ 0.013), one SNP in SORCS2 (rs7694823: P ¼ 0.015) and two SNPs in SORL1 showed nominally significant association in at least one of the FAD data sets (rs2298813: P ¼ 0.012; rs2070045: P ¼ 0.031).
To validate these initial results, we investigated a second series of SNPs from the SORCS1, SORCS2 and SORL1 genes in the two FAD discovery data sets ( Table 1 and Fig. 1b) . We did not detect any association with the additional SNPs in SORCS1 (a total of nine SNPs) or in SORCS2 (a total of six SNPs) (Supplementary Tables 2 and 3) . However, six SNPs clustered in two distinct regions of the SORL1 gene were significantly associated with Alzheimer disease in at least one discovery data set and also in at least one replication data set ( Table 2  and Supplementary Table 4 online) . Notably, at five of these SNPs, the alleles associated with Alzheimer disease were identical in both the discovery and replication data sets ( Fig. 2 ) and VPS35 (not shown) and acts as a sorting receptor for APP holoprotein. Absence of SORL1 switches APP holoprotein away from the retromer recycling pathway and instead directs APP into the bsecretase cleavage pathway, increasing APPsb production ( Fig. 3c) and then into the g-secretase cleavage pathway to generate Ab (see Fig. 3b ).
Blockade of the retromer complex (RC) by inhibiting retromer complex proteins such as VPS26A (Fig. 3d) Table 5 ). This region of SORL1 also showed significant haplotypic associations in the MIRAGE African American sibships. However, the haplotypic associations at SNPs 23-25 in the MIRAGE African American sibships were with different haplotypes (global P ¼ 0.0043; disease-associated 'ACT' haplotype-P ¼ 0.0025, frequency ¼ 0.513; protective 'ACC' haplotype P ¼ 0.0044, frequency ¼ 0.403; Table 3 and Supplementary Table 5 ). The conclusion that there are at least two distinct regions of SORL1 that are associated with Alzheimer disease in different populations was supported when we examined shorter or longer haplotypes (Supplementary Tables 6-9 online).
To provide a completely independent confirmation of the association between Alzheimer disease and SORL1, we genotyped SNPs 4, 5, 8, 9, 12, [19] [20] [21] [22] [23] [24] [25] and analyzed them at an independent facility in three series of American affected individuals and controls of European ancestry ascertained at the Mayo Clinic (n ¼ 1,405 late-onset Alzheimer disease cases and 2,124 controls; Supplementary Table 1 ) 27, 28 . The north European Caucasians and the Mayo data sets have slightly different allele frequencies and haplotype structures and may therefore have slightly different ancestral origins. Nevertheless, we observed significant associations at SNPs 4, 12, 19 and 23-25 in the overall Mayo data set (single-SNP: 0.009 r P r 0.046). Two of the three sub-data sets individually generated highly significant results (0.001 o P o 0.007) for one or more of these SNPs (Table 4) . Notably, the alleles and haplotypes at SNPs 19 and 22-25 that were associated with increased risk for Alzheimer disease in the Mayo data Marker intervals are calculated on the basis of NCBI locations. SNPs are referred to in this paper by sequential numbers (marker number) reflecting their relative physical map positions. Orientation or strand information was obtained from NCBI: 'fwd/T' refers to forward or top strand; 'rev/B' refers to reverse or bottom strand. The linkage disequilibrium maps for these SNPs are given in Supplementary Table 3 .
sets (boldface in Tables 4 and 5) were the same as those associated with increased risk for Alzheimer disease in both the north European FAD data set and in the north European case-control data set (boldface in Tables 2 and 3) . When we considered all of the Caucasian casecontrol samples together (n ¼ 1,583 Alzheimer disease cases and 2,366 controls), the associations remained robust (single-SNP: 0.002 r P r 0.04, with three SNPs giving P o 0.008). Notably, both the Mayo data set and the overall Caucasian case-control data set also detected association with SNP 4 (P ¼ 0.009 and P ¼ 0.002, respectively), a result not evident in the individual data sets.
Cell biology of SORL1
The SNPs and haplotypes identified here are unlikely to be the actual causal variants. We sequenced the exons and immediate intron-exon boundaries in carriers of the disease-associated haplotypes at SNPs 8-10 or SNPs 22-24, and we investigated SORL1 splice forms recovered by RT-PCR. However, we did not identify any pathogenic sequence variants enriched in individuals with Alzheimer disease (Supplementary Table 10 online). The possibility that the observed associations with SNPs inside SORL1 might reflect pathogenic variants outside SORL1 can be excluded because none of the SNPs flanking the 5¢ and 3¢ ends of SORL1 showed association with Alzheimer disease. It is therefore likely that the observed associations with SNPs reflect the presence of pathogenic variants within the intronic sequences of SORL1 near SNPs 8-10 and 22-24. We speculate that these putative intronic SORL1 variants might modulate the cell type-specific transcription or translation of SORL1 in carriers of the Alzheimer diseaseassociated haplotypes. This hypothesis would be supported by the recent observation of reduced expression of SORL1 in neurons but not glia of some individuals with sporadic Alzheimer disease 12 . Direct exploration of this hypothesis is difficult. First, the variations in SORL1 expression in Alzheimer disease brain have been cell type specific, with SORL1 expression depressed in neurons but not glia 12 . Second, there are only limited brain tissue samples from individuals where SORL1 SNP marker phase (and thus haplotypes) are known. Nevertheless, tentative support for the hypothesis that Alzheimer disease-associated haplotypes in SORL1 may be associated with reduced SORL1 transcription is provided by quantitative real-time PCR studies of SORL1 expression in lymphoblasts from carriers of the CTT Alzheimer disease haplotype at SNPs 22-24. Sufficient numbers of samples were not available to test the effects of SNPs 8-10. These experiments demonstrated that SORL1 was expressed in Alzheimer disease haplotype carriers at less than half the levels observed in obligate carriers of non-Alzheimer disease haplotypes (10,324 ± 8,215 arbitrary units in carriers versus 23,650 ± 17,999 in non-carriers (mean ± s.d.), normalized to b-actin mRNA; P o 0.05, two-tailed Mann-Whitney U-test; n ¼ 8 independent samples; n ¼ 3 replications). However, it is also of note that univariate regression analyses showed that SORL1 haplotype status accounted for only B14% of this variance (P ¼ 0.08). This latter result implies that other genetic and nongenetic factors can also modulate SORL1 expression and, perhaps, therefore, risk for Alzheimer disease.
The observation that specific genetic variants in SORL1 are associated with Alzheimer disease and that these same variants may be accompanied by reduced SORL1 expression is significant for the following reasons. First, these observations lead to the conclusion that the previously reported reductions in SORL1 expression in neurons in sporadic Alzheimer disease are likely to be causal rather than simply reactive. This notion is supported by that fact that SORL1 expression is not altered in other types of Alzheimer disease with known etiology (for example, FAD with mutant PSEN1) 12, 29 . Second, Haplotypes that show increased risk for Alzheimer disease in at least two independent data sets are shown in boldface. Haplotypes that show reduced risk in at least two independent data sets are underlined. Complete data for all SNPs is contained in Supplementary Table 5 .
Hap P value, haplotype P value (Haplo.stats v1.1.1); Global sim P, permutation-based global haplotypic P value reported by FBAT (hbat -p option) or
Haplo.stats; *, sample size too small to generate meaningful result; Info families, number of informative families. 
A R T I C L E S
these observations raise the question of how changes in SORL1 expression or function might affect risk for Alzheimer disease. To explore this question, we undertook cell biological experiments, demonstrating that SORL1 directly binds APP and differentially regulates its sorting into endocytic or recycling pathways (Fig. 1a) . Coimmunoprecipitation experiments in native HEK cells demonstrated that endogenous SORL1 physically interacts with the endogenous APP holoprotein (Fig. 2) and with VPS35 (which drives cargo selection in the retromer via VPS10-containing proteins like SORL1 (ref. 30 and data not shown). SORL1, however, does not bind to APP C-terminal fragments produced by a-, b-or g-secretase cleavage (Fig. 2) . These protein-protein interactions are specific because SORL1 does not bind to other type 1 membrane proteins (for example, BACE1 (ref. 31) and Fig. 3) or to VPS26 (which links VPS35 to the other structural elements of the retromer (ref. 30 and data not shown).
The interaction between SORL1, VPS35 and APP holoprotein provides a mechanism by which SORL1 can regulate differential sorting of APP into the retromer recycling pathway or into the late endosomal pathway (where APP undergoes b-and g-secretase cleavage to generate Ab). In agreement with this hypothesis, overexpression of SORL1, which would be predicted to divert APP holoprotein into the retromer recycling pathway, results in decreased Ab production (82% of control, P o 0.05, n ¼ 5 replications; Fig. 3a) . Conversely, short interfering RNA (siRNA) suppression of SORL1 expression, which we speculate might mimic the effects of Alzheimer disease-associated variants in SORL1, results in deflection of APP holoprotein away from the retromer recycling pathway and into the late endosome-lysosome pathway. As would be predicted, siRNA suppression of SORL1 leads to (i) overproduction of the soluble N-terminal ectodomain of APP (APPsb) generated by BACE1 cleavage of APP holoprotein (149.45% ± 9.66 of control (mean ± s.e.m.), P o 0.0001, n ¼ 5 replications; Fig. 3c ) and (ii) overproduction of Ab by the subsequent g-secretase cleavage of the APP C-terminal stub generated by BACE1 (Ab40, 189% of control; Ab42, 202% of control, P o 0.001; three independent siRNA oligonucleotides with five replications each; Fig. 3b ). Our conclusion that SORL1 regulates sorting of APP into the retromer-recycling pathway is supported by the observation of identical effects after suppression of the retromer proteins VPS26A (Ab40, 186% of control value; Ab42, 183% of control value, P o 0.001, n ¼ 5 replications; Fig. 3d ) or VPS35 (ref. 13 ). These results and conclusions are in very good agreement with independent reports that appeared during preparation of this manuscript 14, 15 .
DISCUSSION
Taken together, our results suggest that genetic and possibly environmentally specified changes in SORL1 expression or function are causally linked to the pathogenesis of Alzheimer disease and have a modest effect on risk for this disease. The precise identity of the genetic effectors in SORL1 remains to be determined. However, the results described here imply that (i) there are several different Alzheimer disease-associated allelic variants in distinct regions of the SORL1 gene in different populations; (ii) these variants are likely to be in intronic regulatory sequences that might govern cell type-specific or tissue-specific expression of SORL1 and (iii) these variants affect this risk by altering the physiological role of SORL1 in the processing of APP holoprotein. In sharp contrast to APOE (where APOE e4 is associated with Alzheimer disease in most data sets 32 ), no single SORL1 SNP or haplotype is associated with increased risk for Alzheimer disease in all six data sets, and some data sets fail to show any association with SORL1. However, four points mitigate concerns that the association between SORL1 and Alzheimer disease is spurious. First, the association was initially identified using conservative family-based association tests, which are less sensitive to confounding due to population stratification 33 . Second, at each set of SNP clusters, the same alleles and haplotypes were associated with increased risk for Alzheimer disease in at least three unrelated data sets, some of which were drawn from different ancestral origins. Third, the discovery of association with different SNPs in different populations does not indicate a spurious result. The association of disease with a single allele in all data sets (that is, an APOE e4-like association) is not a universal observation for either complex or monogenic diseases 17 . Thus, the Table 3 ). Haplotypes with reduced risk of Alzheimer disease are underlined but are different from those in the north European data sets, suggesting the potential existence of several protective alleles in this region. MAF, minor allele frequency; OR, odds ratio; P, single-SNP χ 2 P value; Hap P value, haplotype P value (Haplo.stats v1.1.1); Global sim P, permutation-based global haplotypic P value reported by FBAT (hbat -p option) or Haplo.stats; *, sample size too small to generate meaningful result. occurrence of pathogenic mutations across multiple domains of disease genes (allelic heterogeneity) and the absence of these variants in some data sets (locus heterogeneity) are frequently observed in both monogenic and complex traits 34, 35 . Fourth, the absence of significant associations in two data sets (MIRAGE Caucasian sibships and the Mayo Rochester data set) does not negate the findings from the other data sets. There are several potential explanations for the failure to detect a significant association in these two data sets. These potential explanations include (i) insufficient power to reliably detect the association in all series; (ii) locus heterogeneity (that is, non-SORL1 causes might have been overrepresented and SORL1-associated causes underrepresented in some data sets) or (iii) allelic heterogeneity (that is, the association may have been obscured if the biologically active SORL1 alleles had occurred on multiple SNP backgrounds in some data sets). The probable existence of allelic heterogeneity has important implications for replication studies. Such studies will need to assess a battery of SNPs focused on data sets with as homogeneous a genetic background as possible.
Our results also resolve the conundrum concerning the significance of reduced expression of SORL1 and several other genes potentially involved in APP trafficking in brain tissue from individuals with Alzheimer disease. Our results argue that the reduction in SORL1 expression in affected brain tissue is likely to be a primary and pathogenic event, whereas the reduction in VPS35 expression is likely to be a secondary event.
Finally, our data demonstrate that SORL1 has a key physiological role in the differential sorting of APP holoprotein. In the presence of SORL1, APP holoprotein is recovered via the retromer. In the absence of SORL1, APP is released into late endosomal pathways, where it is subjected to b-secretase cleavage, and subsequently g-secretase cleavage, which generate Ab (Fig. 1a) .
METHODS
Subjects. Informed consent was obtained from all participants using procedures approved by institutional review boards at each of the clinical research centers collecting human subjects. The clinical diagnosis of 'probable' or 'possible' Alzheimer disease was defined according to the National Institute of Neurological and Communication Disorders and Stroke-Alzheimer's Disease and Related Disorders Association (NINCDS-ADRDA) diagnosis criteria at clinics specializing in memory disorders. Clinical characteristics of the north European, MIRAGE, Caribbean Hispanic FAD, Israeli Arab and Mayo Caucasian American data sets are summarized in Supplementary Table 1 (refs. 19,20,22-25,27,28) . The north European case-control set is drawn from the same populations as the north European FAD data set 20, 22 . The three Mayo data sets were drawn from Caucasian affected individuals and controls assessed in clinical series at the Rochester and Jacksonville Mayo Clinics or from Caucasian brains in which the presence or absence of Alzheimer disease was determined neuropathologically by autopsy ('AUT' in Supplementary Table 1 ).
Genetic analyses. Genotyping was performed using the GenomeLab SNPstream System, and primer sets were as in Supplementary (Beckman Coulter). We genotyped 100 DNA samples twice for every SNP marker (the concordance rate was 499%). APOE was genotyped as described 5 Statistical analyses. SNP marker data were assessed for deviations from HardyWeinberg equilibrium (using Pedstats software) and for mendelian inheritance errors (using Pedcheck software). Single-point family-based association was assessed with FBAT v1.5.5 (ref. 36) , using an additive genetic model with the null hypothesis of no linkage and no association. Allele frequencies were estimated by FBAT using the EM algorithm. APOE e4 carrier status was included in the analyses using PBAT v2. 6 (refs. 37-40) . The w 2 test (or the Fisher's exact test) was used to assess genotypic and allelic associations between Alzheimer disease. Multivariate logistic regression analysis was performed to adjust for APOE e4, sex and age-at-onset or age-at-examination.
Statistical significance and multiple testing corrections. The Benjaminicorrected false discovery rate (FDR) 41 was used with a cutoff level of 0.1 to correct for multiple testing. The P values presented are nominal P values. The cutoff P values for significance in each data set are shown in the table legends.
Linkage disequilibrium. LD structure was examined using Haploview. Haplotype blocks were defined using the confidence intervals algorithm. The default settings were used in these analyses, which create 95% confidence bounds on D¢ to define SNP pairs in strong LD.
Haplotype analyses. Haplotype analyses were carried out with a sliding window of three contiguous SNPs using FBAT for family data and Haplo.stats v1.1.1 for case-control data 16, 26, [42] [43] [44] . The analyses were repeated using sliding windows of two, four, five and six SNPs.
Expression plasmids and cDNA constructs for human SORL1. The cDNA clones encoding APP K670N/M671L Swedish mutation (APP Swe ) and BACE1 (V5-tagged at the C terminus) were as described previously 45, 46 .
Cell culture and transfection. The HEK293 cell line stably expressing APP Swe was as described 47 . Transient transfection of BACE1 cDNA was performed using LipofectAMINE 2000 (Invitrogen).
RNA interference. siRNA oligonucleotides were designed using the online siRNA Design Tool (Dharmacon Research). The siRNAs for SORL1 are in Supplementary Table 3 . The siCONTROL Non-Targeting siRNAs #1 and #2 (Dharmacon Research) were used as a negative control.
Transfections were performed using LipofectAMINE 2000 according to the manufacturer's recommendations. In case of consecutive transfections, cells were split after 24 h and then retransfected 24 h later. After culturing for an additional 24 h, the conditioned medium was collected for the Ab assay, and the cells were harvested for protein blotting.
Antibodies, immunoprecipitation and protein blotting. Antibodies were as follows: mouse monoclonal anti-human LR11/SORL1gp250 (BD Transduction Laboratories) and 5-4-30-19-2 (from H.B.); rabbit antibody to the C terminus of SORL1 (from W.H.); rabbit polyclonal antibody to PS1-NTF (Ab14, from S. Gandy, Temple University); mouse monoclonal anti-myc (Invitrogen); rabbit polyclonal antibody to the C terminus of APP (Sigma) and anti-BACE1 (EE-17, Sigma). Proteins were immunoprecipitated in 1% digitonin 48 , subjected to protein blot and visualized by ECL (Amersham).
Ab, APPsa and APPsb assays. Ab40 and Ab42 peptide levels were measured by sandwich ELISA 49 . APPs, APPsa and APPsb were measured by protein blotting using antibodies 22C11 (Chemicon), 2H3 and SW192 (Elan Pharmaceuticals), respectively. Differences were assessed by two-tailed Student's t-test.
Quantitative RT-PCR. PCR primer pairs targeting SORL1 exon 23 were as in Supplementary Table 3 . Total RNA (5 mg) was reverse transcribed using a random hexamer. Real-time PCR was performed in a 384-well format using an ABI Prism 7900HT instrument and the Sybr Green detection method. Samples were analyzed in triplicate, and mean expression levels corresponding to SORL1 mRNA expression were normalized to b-actin mRNA levels.
URLs. Haploview is available at http://www.broad.mit.edu/mpg/haploview/ index.php.
Note: Supplementary information is available on the Nature Genetics website.
